scholarly journals Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum  -lactamases, AmpC  -lactamases and reduced susceptibility to carbapenems using an in vitro model

2009 ◽  
Vol 64 (4) ◽  
pp. 824-828 ◽  
Author(s):  
G. G. Zhanel ◽  
P. J. Baudry ◽  
F. Tailor ◽  
L. Cox ◽  
D. J. Hoban ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
In Vitro Model ◽  
Clinical Isolates ◽  
Serum Concentrations ◽  
Extended Spectrum ◽  
Vitro Model

52 An in vitro model for determination of the rate of resistance development in HIV

1993 ◽  
Vol 20 ◽  
pp. 68 ◽  
Author(s):  
L. Vrang ◽  
C. Rydergȧrd ◽  
C. Ȧhgren ◽  
J. Wahlberg ◽  
M. Uhlén ◽  
...  
Keyword(s):  
In Vitro Model ◽  
Resistance Development ◽  
Vitro Model

Determination of Functional ABCG2 Activity and Assessment of Drug–ABCG2 Interactions in Dairy Animals Using a Novel MDCKII In Vitro Model

2013 ◽  
Vol 102 (2) ◽  
pp. 772-784 ◽  
Author(s):  
Louise Wassermann ◽  
Sandra Halwachs ◽  
Stefan Lindner ◽  
Kerstin U. Honscha ◽  
Walther Honscha
Keyword(s):  
In Vitro Model ◽  
Dairy Animals ◽  
Vitro Model

Clearance of Levofloxacin by an in Vitro Model of Continuous Venovenous Hemodialysis (CVVHD)

2007 ◽  
Vol 30 (10) ◽  
pp. 889-895 ◽  
Author(s):  
S. Siewert ◽  
B. Drewelow ◽  
S.C. Mueller
Keyword(s):  
In Vitro Model ◽  
Urea Clearance ◽  
Flow Rates ◽  
Dialysate Flow ◽  
Dialysate Flow Rate ◽  
Continuous Venovenous Hemodialysis ◽  
Vitro Model ◽  
Positive Correlations

Information about the elimination and the adequate dosing of levofloxacin during renal replacement therapy is scarce. The aim of this study was to characterize in vitro the elimination of levofloxacin during continuous venovenous hemodialysis (CVVHD) and to investigate whether the CVVHD clearances of creatinine and urea are correlated with the levofloxacin clearance in order to facilitate dosage adjustments. An in vitro model of CVVHD was established using five dialyzer membranes at varying dialysate flow rates applied in the clinical setting (8, 16, 25, 33 and 41 ml/min). Plasma and dialysate samples were drawn for determination of levofloxacin, creatinine and urea concentrations to evaluate clearances by CVVHD. During CVVHD, the clearance of levofloxacin varied between 9.02 and 33.30 ml/min, depending on the chosen setup. Positive correlations (p<0.001) were received for: dialysate flow rate (QD) and creatinine/urea clearances (R>0.93); QD and levofloxacin clearance (R 0.59–0.71); levofloxacin and creatinine clearance (R 0.69–0.75); and levofloxacin and urea clearance (R 0.56–0.75) as well. When dosing critically ill patients, therefore, extracorporeal as well as total clearance of levofloxacin should be considered.

Comparison of Two Different In Vivo Models and an In Vitro Model for Caloric Determination of Four Novel Fiber Ingredients

2013 ◽  
Vol 61 (50) ◽  
pp. 12374-12379 ◽  
Author(s):  
Sarah Cervantes-Pahm ◽  
Brenda K. Knapp ◽  
Beob G. Kim ◽  
Yanhong Liu ◽  
Carl M. Parsons ◽  
...  
Keyword(s):  
In Vitro Model ◽  
In Vivo Models ◽  
Vitro Model
Sign in / Sign up

Export Citation Format

Share Document